![Novo Nordisk's Rybelsus launch defies 2020 full-year sales expectations, despite the economic impacts of the Covid-19 pandemic - Pharmaceutical Technology Novo Nordisk's Rybelsus launch defies 2020 full-year sales expectations, despite the economic impacts of the Covid-19 pandemic - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2021/02/shutterstock_1224254950-1.jpg)
Novo Nordisk's Rybelsus launch defies 2020 full-year sales expectations, despite the economic impacts of the Covid-19 pandemic - Pharmaceutical Technology
![Novo Nordisk to price oral diabetes drug Rybelsus similar to injectable Ozempic | S&P Global Market Intelligence Novo Nordisk to price oral diabetes drug Rybelsus similar to injectable Ozempic | S&P Global Market Intelligence](https://www.snl.com/articles/399787165.png)
Novo Nordisk to price oral diabetes drug Rybelsus similar to injectable Ozempic | S&P Global Market Intelligence
![NOVO NORDISK LAUNCHES NEW ORAL THERAPY FOR DIABETES CARE PATIENTS “RYBELSUS” | by Bare Sky Marketing — Healthcare Content Writing | Medium NOVO NORDISK LAUNCHES NEW ORAL THERAPY FOR DIABETES CARE PATIENTS “RYBELSUS” | by Bare Sky Marketing — Healthcare Content Writing | Medium](https://miro.medium.com/max/614/1*qQudqyLwOskE4KV2GaIjng.jpeg)
NOVO NORDISK LAUNCHES NEW ORAL THERAPY FOR DIABETES CARE PATIENTS “RYBELSUS” | by Bare Sky Marketing — Healthcare Content Writing | Medium
![Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com](http://midgardfinance.com/companies/N/NOVO-B.CO/novo2020q2_by_class_us.png)